Acrux Limited has released a press release.
Acrux licenses Lenzetto for Australian market for AUD5.4m
Earlier from Acrux
- Capital Gains Tax exemptions remain in place for Acrux
- Acrux raises $1.6 million via Share Placement
- Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
- Acrux strategy focuses on Female Testosterone for low libido